Adam C ElNaggar
Overview
Explore the profile of Adam C ElNaggar including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
414
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sha Y, Ortiz J, Bristow S, Loranger K, Meng L, Zhao X, et al.
Genet Med Open
. 2025 Feb;
3:101914.
PMID: 39902189
Purpose: Although up to 25% of germline variants are predicted to affect splicing, most are classified as variants of uncertain significance (VUS) because of the limited understanding of their functional...
2.
Liu Y, Mathews C, Simpkins F, Cadoo K, Provencher D, McCormick C, et al.
Cancer
. 2025 Jan;
131(2):e35707.
PMID: 39817648
Background: LIGHT (oLaparib In HRD-Grouped Tumor types; NCT02983799) prospectively evaluated olaparib treatment in patients with platinum-sensitive relapsed ovarian cancer (PSROC) assigned to cohorts by known BRCA mutation (BRCAm) and homologous...
3.
Basu A, Au C, Kommalapati A, Kandala H, Sudhaman S, Mahmood T, et al.
JCO Precis Oncol
. 2024 Dec;
8:e2400667.
PMID: 39693589
Purpose: Tumor-informed circulating tumor DNA (ctDNA) has shown promise as a biomarker for treatment response monitoring (TRM) in a variety of tumor types, with the potential to improve clinical outcomes....
4.
Schrock-Kelley S, Souter V, Hall M, Sha Y, Sengupta U, ElNaggar A, et al.
Commun Med (Lond)
. 2024 Sep;
4(1):185.
PMID: 39349798
Background: Approximately 15% of colorectal cancers (CRCs) are associated with germline mutations. There is increasing adoption of DNA-based assays for molecular residual disease (MRD) and growing evidence supporting its clinical...
5.
Correa A, Kalashnikova E, Wu H, Winters R, Balcioglu M, Sudhaman S, et al.
Oncologist
. 2024 Jul;
29(10):887-893.
PMID: 39013784
Background: Despite complete resection, 20%-50% of patients with localized renal cell carcinoma (RCC) experience recurrence within 5 years. Accurate assessment of prognosis in high-risk patients would aid in improving outcomes....
6.
Sfakianos J, Basu A, Laliotis G, Cumarasamy S, Rich J, Kommalapati A, et al.
Eur Urol Oncol
. 2024 Jul;
PMID: 39013741
Background And Objective: Despite curative-intent radical cystectomy (RC), patients with muscle-invasive bladder cancer (MIBC) are at high risk of recurrence. Biomarkers are urgently needed to refine prognostication and selection of...
7.
Recio F, Scalise C, Loar P, Lumish M, Berman T, Peddada A, et al.
Gynecol Oncol
. 2024 Jan;
182:63-69.
PMID: 38262240
Introduction: Among uterine malignancies, endometrial cancer (EC) is the most common cancer of the female reproductive tract. Traditionally, risk stratification in EC is determined by standard clinicopathological risk factors. Although...
8.
Friedman C, DSouza A, Bello Roufai D, Tinker A, de Miguel M, Gambardella V, et al.
Gynecol Oncol
. 2024 Jan;
181:162-169.
PMID: 38211393
Objective: HER2 mutations are associated with poor prognosis and are detected in 3-6% of cervical cancers. Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, had activity in several HER2-mutant cancer types...
9.
Randall L, OMalley D, Monk B, Coleman R, Gaillard S, Adams S, et al.
Gynecol Oncol
. 2023 Oct;
178:161-169.
PMID: 37890345
Objective: This study assessed the efficacy, safety, and health-related quality of life (HRQoL) of the treatment regimen of dostarlimab, a programmed death-1 inhibitor, combined with niraparib, a poly (ADP-ribose) polymerase...
10.
Lindskrog S, Birkenkamp-Demtroder K, Nordentoft I, Laliotis G, Lamy P, Christensen E, et al.
Clin Cancer Res
. 2023 Oct;
29(23):4797-4807.
PMID: 37782315
Purpose: To investigate whether circulating tumor DNA (ctDNA) assessment in patients with muscle-invasive bladder cancer predicts treatment response and provides early detection of metastatic disease. Experimental Design: We present full...